Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial.
about
Primary Antibiotic Resistance of Helicobacter pylori in China.Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Treatment of Helicobacter pylori infection 2017.Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication.
P2860
Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Antibiotic resistance and CYP2 ...... single-centre clinical trial.
@en
type
label
Antibiotic resistance and CYP2 ...... single-centre clinical trial.
@en
prefLabel
Antibiotic resistance and CYP2 ...... single-centre clinical trial.
@en
P2093
P2860
P356
P1476
Antibiotic resistance and CYP2 ...... single-centre clinical trial.
@en
P2093
Anjiang Wang
Dongsheng Liu
Huifang Xiong
Huilie Zeng
Huiqiang Yu
Jiuhong Ma
Junbo Hong
Kunhe Zhang
Nonghua Lu
P2860
P304
P356
10.1093/JAC/DKW118
P407
P577
2016-04-21T00:00:00Z